Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea

Abstract

Objectives: The aim of this study was to evaluate the safety and efficacy of fesoterodine fumarate (fesoterodine; Toviaz) in Korean patients with overactive bladder (OAB) in routine clinical practice. Methods: This was an open-label, non-interventional, prospective, post-marketing surveillance study submitted to the Korean Ministry of Food and Drug Safety. A total of 3109 patients aged ≥18 years with OAB symptoms were prescribed flexible doses of fesoterodine at the investigator’s discretion. Safety was assessed based upon the reporting of adverse events (AEs). Efficacy was evaluated on the basis of patient self-assessment using a bladder diary as well as on the basis of investigator assessment in terms of overall clinical efficacy.

Results: A final analysis was performed on 3107 (99.9%) and 2978 (95.8%) patients for safety and efficacy analysis, respectively. The mean treatment duration of fesoterodine was 83.2 days. The incidence of AEs was 8.5% (265/3107). Common AEs that accounted for more than 1.0% of the total AE incidence included dry mouth (5.4%, 168/3107), constipation (1.5%, 48/3107) and micturition disorder (1.1%, 35/3107). Mean episodes of urinary frequency, urgency, and urgency urinary incontinence (UUI) per 24 hours decreased by 4.0, 2.4, and 0.8, respectively (all p < 0.001). At the final follow-up visit, the investigators found improvement in clinical efficacy for the majority of patients (90.1%, 2684/2978). Limitations of this study include the observational study design and the relatively short treatment duration.

Conclusion: These results suggest that fesoterodine is a well tolerated and effective treatment for Korean patients with OAB in routine clinical practice.

Keywords:

• Antimuscarinic agents
• Fesoterodine
• Overactive bladder
• Post-marketing surveillance

Transparency

Declaration of funding

Pfizer Pharmaceuticals Korea Ltd. sponsored this research.

Declaration of financial/other relationships

THK and SEL have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article. H-EL has disclosed that he is an employee of Pfizer Pharmaceuticals Korea Ltd. K-SL has disclosed that he has received research grants and speaker honoraria from Pfizer.

CMRO peer reviewer 1 has disclosed receiving grants from Astellas, and serving as a consultant to Astellas and Pfizer. CMRO peer reviewer 2 has no relevant financial or other relationships to disclose.